Mahajan Pramod B
Department of Pharmaceutical, Biomedical and Administrative Sciences, College of Pharmacy and Health Sciences, Drake University, Des Moines, Iowa, 50311, USA.
AAPS J. 2016 May;18(3):605-11. doi: 10.1208/s12248-016-9903-4. Epub 2016 Mar 23.
Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effects, and biocompatible metabolism, in addition to legal and logistic advantages. However, their clinical utility is limited, among other things, by their high immunogenic potential and/or variable therapeutic efficacy in different patient populations. Both of these issues, also commonly experienced with small molecule drugs, have been addressed effectively in a number of cases by the successful application of pharmacogenomic tools and approaches. In this introductory article of the special issue, we review the current state of application of pharmacogenomics to BTs and offer suggestions for further expansion of the field.
生物治疗药物(BTs)是增长最快的药物分子类别之一,除了具有法律和物流方面的优势外,由于其相对较高的特异性、低脱靶效应和生物相容性代谢,与传统小分子药物相比具有若干优势。然而,它们的临床应用受到限制,尤其是其高免疫原性潜力和/或在不同患者群体中的治疗效果差异。小分子药物也普遍存在这两个问题,在许多情况下,通过成功应用药物基因组学工具和方法已有效解决。在本期特刊的这篇介绍性文章中,我们回顾了药物基因组学在生物治疗药物方面的应用现状,并为该领域的进一步拓展提供建议。